Literature DB >> 16360364

Relation of systemic ventricular function quantified by myocardial performance index (Tei) to cardiopulmonary exercise capacity in adults after Mustard procedure for transposition of the great arteries.

Kambiz Norozi1, Reiner Buchhorn, Valentin Alpers, Jan O Arnhold, Stephan Schoof, Monika Zoege, Siegfried Geyer, Armin Wessel.   

Abstract

After Mustard repair for transposition of the great arteries, the right ventricle serves as a chronically overloaded systemic ventricle (SV). Thus, during long-term follow-up, dysfunction of the right ventricle with consecutive heart failure (HF) is not unusual. Early signs and symptoms of HF are depressed parameters of right ventricular (RV) function at rest and exercise intolerance. It was hypothesized that the measurement of RV function parameters, N-terminal pro-brain natriuretic peptide (NT-pro-BNP), and peak oxygen uptake (VO2max) during exercise testing were suitable for the early detection of subclinical HF. In 33 asymptomatic adolescents and adults who had undergone Mustard repair, RV function was analyzed by the myocardial performance index (Tei index). NT-pro-BNP and VO2max were also determined. The corresponding data from 52 patients operated on for left-to-right shunt defects without residual lesions served as reference data. In patients who underwent the Mustard procedure, the Tei index and NT-pro-BNP were elevated (mean Tei index of the SV 0.63 +/- 0.17 vs 0.34 +/- 0.05, p <0.002; mean NT-pro-BNP 240 +/- 230 vs 57 +/- 39 pg/ml, p <0.0001), and VO2max was reduced (27 +/- 6 vs 32 +/- 6 ml x kg(-1) x min(-1), p <0.002). A good correlation was found between the Tei index and VO2max (r = -0.83, p <0.0001). In conclusion, RV function is depressed in most patients with Mustard repair. Ventricular dysfunction in such asymptomatic or minimally symptomatic patients can be detected by measurement of the Tei index, NT-pro-BNP, and VO2max. These parameters are simple and reliable screening methods to stratify patients with impaired cardiac dysfunction before they become symptomatic.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16360364     DOI: 10.1016/j.amjcard.2005.07.096

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Functional implications of the right ventricular myocardial performance index in patients after surgical repair of tetralogy of Fallot.

Authors:  Eddie W Y Cheung; Wendy W M Lam; Stephen C W Cheung; Yiu-Fai Cheung
Journal:  Heart Vessels       Date:  2008-04-04       Impact factor: 2.037

Review 2.  Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology.

Authors:  Werner Budts; Jolien Roos-Hesselink; Tanja Rädle-Hurst; Andreas Eicken; Theresa A McDonagh; Ekaterini Lambrinou; Maria G Crespo-Leiro; Fiona Walker; Alexandra A Frogoudaki
Journal:  Eur Heart J       Date:  2016-01-18       Impact factor: 29.983

3.  Relationship between Exercise Parameters and Noninvasive Indices of Right Ventricular Function in Patients with Biventricular Circulation and Systemic Right Ventricle.

Authors:  Keri M Shafer; Nina Mann; Rebecca Hehn; Ana Ubeda Tikkanen; Anne Marie Valente; Tal Geva; Naomi Gauthier; Jonathan Rhodes
Journal:  Congenit Heart Dis       Date:  2015-01-19       Impact factor: 2.007

Review 4.  The potential and limitations of plasma BNP measurement in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an update.

Authors:  Massimiliano Cantinotti; Yuk Law; Simona Vittorini; Maura Crocetti; Marotta Marco; Bruno Murzi; Aldo Clerico
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

5.  Global longitudinal strain correlates to systemic right ventricular function.

Authors:  Daniel Samarai; Sandra Lindstedt Ingemansson; Ronny Gustafsson; Ulf Thilén; Joanna Hlebowicz
Journal:  Cardiovasc Ultrasound       Date:  2020-01-27       Impact factor: 2.062

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.